Trevi Therapeutics, Inc.
TRVI
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.5B
$17.26
▲ +1.17%
P/E
-51.10
Mkt Cap
$2.5B
52-Wk Range
$6.98–$20.22
52-Week Range
$6.98 - $20.22
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 127.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Exclusive license agreement with Endo Pharmaceuticals for nalbuphine formulations
- Repurposing established pharmaceutical with known safety profile reduces development risk
- Targeting underserved patient populations with limited existing treatment options
- Oral extended-release formulation provides improved patient convenience versus alternatives
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Phase IIb/III clinical trial progression and potential FDA approval pathway
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+27.9% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying TRVI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 6, 2026
Reported EPS of -$0.11 vs -$0.11 consensus (-0.5% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-0.5%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
9 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Morgan Stanley · Aug 7, 2026
vs Industry
How TRVI stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related